Posted on October 15, 2018 in: Professional Practice
By Thy Mai, Pharm.D., pharmacy resident, SpartanNash, Grand Rapids
In October 2017, the Food and Drug Administration (FDA) approved Sanofi's Toujeo® (insulin glargine 300 units/mL) Max SoloStar®. This new pen is the highest capacity long-acting insulin pen currently available on the market. This new pen device option is available for patients who require more than 80 units per dose. With the ability to deliver a dose of up to 160 units/mL, the Toujeo Max Solostar® pen may help reduce the number of injections needed to deliver the required dosage for some adults with diabetes. Depicted in the chart below are the differences between the two Toujeo® pen options.
Toujeo Max SoloStar®
Dose adjusted by: 2 units
Dose adjusted by: 1 unit
Max dose: 160 units per injection
Max dose: 80 units per injection
Cartridge: 900 units
Cartridge: 450 units
3 mL and 900 units per pen
1.5 mL and 450 units per pen
1 box contains 2 pens (6 mL and 1800 units total) per box
1 box contains 3 pens (4.5 mL and 1350 units total) per box
The new Toujeo Max SoloStar® pen device still offers the same qualities as the Toujeo® pen such as:
1. Toujeo Max Solostar® [package insert]. Bridgewater, NJ: Sanofi; 2018.